本文是一项 1 期研究（TIMEPOINT），评估 MTL-CEBPA 联合派姆单抗（pembrolizumab）治疗晚期实体瘤的效果。研究发现该联合治疗安全可耐受，能改变肿瘤微环境，从免疫荒漠转变为炎症状态，降低免疫抑制，为实体瘤免疫治疗提供新思路。 ### 研究背景 免疫检查点阻断 ...

A recent study has unveiled the critical roles of two transcription factors, MAFB and CEBPA, in the development of hypospadias, a common congenital malformation affecting male urethral development.